SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 8,650,000 shares, a decline of 11.8% from the January 31st total of 9,810,000 shares. Based on an average trading volume of 2,700,000 shares, the days-to-cover ratio is presently 3.2 days.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in shares of SELLAS Life Sciences Group during the 3rd quarter worth about $78,000. Virtu Financial LLC lifted its position in shares of SELLAS Life Sciences Group by 24.1% in the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock worth $99,000 after acquiring an additional 15,398 shares during the period. Northern Trust Corp grew its holdings in shares of SELLAS Life Sciences Group by 33.6% during the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company’s stock worth $140,000 after purchasing an additional 33,878 shares in the last quarter. State Street Corp increased its position in shares of SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after purchasing an additional 40,500 shares during the period. Finally, Opus Capital Group LLC lifted its position in SELLAS Life Sciences Group by 5.5% in the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock worth $248,000 after purchasing an additional 12,400 shares during the period. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Down 2.0 %

SLS stock traded down $0.03 during trading hours on Thursday, hitting $1.21. The company’s stock had a trading volume of 71,292 shares, compared to its average volume of 3,269,802. The company has a market capitalization of $84.81 million, a PE ratio of -1.75 and a beta of 2.43. The stock has a 50 day moving average price of $1.17 and a two-hundred day moving average price of $1.18. SELLAS Life Sciences Group has a 12 month low of $0.77 and a 12 month high of $1.84.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.